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care and office based chest medicine clinics. A convenience sam-
ple of 500 was selected.
Results We report the characteristics of the first 250 COPD
patients from our ongoing 500 patient survey.
Basic demographics 55% Male, 45% Female. Mean age patients
68 ± 12 yrs, all patients were previous smokers with 56 ± 10
pkt/yrs smoking history. 34% remain current smokers.
Mean FEV1 48% ± 10%, Mean FEV1/FVC ratio 49% ± 10.
Median mMRC dyspnea score 2. Mean CAT score 18 ± 10
(Range 0–38).
GOLD Stage Classification 13% GOLD Stage A, 67% GOLD
Stage B, 1% GOLD Stage C and 19% GOLD Stage D.
Current treatment LAMA (long-acting muscarinic antagonist)
was prescribed to over 90% of all patients in groups B, C and D
whereas monotherapy with LABA (long acting beta-agonist) or
dual bronchodilation with LABA/LAMA therapy was prescribed
to less than 5%.
There was significant overtreatment with ICS/LABA in all cate-
gories with high dose ICS (inhaled corticosteroid) being preferred.
20% of patients in GOLD Stage A where receiving Triple
therapy (LAMA + ICS/LABA) and a further 20% where receiv-
ing monotherapy with ICS/LABA, yet had no history of
exacerbations.
30% of patients in GOLD Stage B where receiving Triple ther-
apy (LAMA + ICS/LABA) yet had no history of exacerbations.
Conclusion Current Canadian Guidelines and the GOLD strat-
egy focus on symptom relief and striving to prevent exacerba-
tions with step-wise prescription of short and long-acting
bronchodilators with individual or combinations of LAMA,
LABA, LAMA/LABA or ICS/LABA inhalers. Patients in GOLD
Group C are rare. Current prescription choices in our survey
does not reflect current evidence or guidelines. We report a
heavy reliance on ICS/LABA along with over prescription of tri-
ple therapy at all stages of disease.
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Background Chronic obstructive pulmonary disease (COPD) is
an inflammatory lung disease characterised by progressive air-
flow limitation. Statins have anti-inflammatory and immunomo-
dulating properties that could alter inflammation of the airways.
The objective of this study is to systematically evaluate the effec-
tiveness of adjunct statin therapy in improving exercise tolerance
and pulmonary function indices in patients with chronic obstruc-
tive pulmonary disease.
Search strategy and inclusion criteria A thorough search was
done using Medline and PubMed, with limits set on studies
involving humans in a randomised control trial in English that
examined the effect of statins in COPD.
Study manoeuvres All the articles retrieved were appraised sepa-
rately and independently by two reviewers for its applicability,
validity and the methodological quality of the randomised con-
trol trials by assessing allocation, blinding, and if follow up rate
was adequate. Disagreements between the reviewers were
resolved by consensus.
Statistical analysis Data collected were analysed using Review
Manager Version 5.2.
Results A total of two articles met the end criteria. Outcome
shows improvement in exercise time (treadmill test) at 95% CI,
with statistically significant benefit with mean difference of
335.18 [253.93, 416.43] favouring Pravastatin group. The stud-
ies show inconclusive results for Pravastatin in improving FEV1
(%) with 95% CI with mean difference of 0.05 [-4.61, 4.7]. The
outcome in total lung capacity shows inconclusive results but
shows a trend toward benefit with 95% CI with mean difference
of -0.08 [-0.46, 0.30]. Inspiratory capacity results at 95% CI
with mean difference of 0.13 [-0.06, 0.32] showed an inconclu-
sive outcome but has a trend toward benefit. Improvement in
the Borg dyspnea score at 95% CI, showing statistically signifi-
cant benefit with mean difference of -2.91 [-3.19, -2.63] favour-
ing the Pravastatin group.
Conclusions Statins already have an established role in treating
cardiovascular patients because of their cholesterol-lowering abil-
ity, but also have anti-inflammatory and immunomodulatory
effects that are beneficial in airway inflammation in COPD. Sta-
tin administration to COPD patients showed amelioration in
exercise tolerance, improvement in dyspnea scores and augmen-
tation in pulmonary function indices. Thus, statins may be useful
as adjunct to currently available therapies as well as improve-
ment in lipid status.
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Introduction Tiotropium (T), a once-daily long-acting muscar-
inic antagonist, is a well-established first-line maintenance treat-
ment in chronic obstructive pulmonary disease (COPD);
olodaterol (O) is a once-daily long-acting b2-agonist that has
recently gained approval in several countries. Two Phase III rep-
licate pivotal studies assessed the efficacy and safety of fixed-
dose combinations of T and O (T+O) delivered via Respimat®
Soft Mist™ inhaler in patients with GOLD 2–4 COPD.
Methods Two 52-week, double-blind, parallel-group studies rand-
omised 5162 patients to O 5 mg, T 2.5 mg, T 5 mg, T+O 2.5/5 mg
or T+O 5/5 mg. Primary efficacy end points were trough forced
expiratory volume in 1 second (FEV1) response (ie change from
baseline), FEV1 area under the curve from 0–3 h and St George’s
Respiratory Questionnaire (SGRQ) total score after 24 weeks.
Pooled data from the two studies are presented here; lung function
from the individual studies will subsequently be provided.
Results All treatments resulted in clinically relevant improve-
ments in lung function, with significant increases with both T
+O doses over the individual components (p1 responses were
0.055 L (O 5 mg), 0.073 L (T 2.5 mg), 0.080 L (T 5 mg), 0.118
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L (T+O 2.5/5 mg) and 0.140 L (T+O 5/5 mg). SGRQ total
scores improved by 5.1 (O 5 mg), 5.7 (T 2.5 mg), 5.6 (T 5 mg),
6.2 (T+O 2.5/5 mg) and 6.8 points (T+O 5/5 mg); differences
between T+O 5/5 mg and O 5 mg and T 5 mg were statistically
significant (p
Conclusions T+O 5/5 mg significantly improved lung function
and provided symptomatic benefit over O 5 mg and T 5 mg.
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Background A reduction in asthma exacerbation risk may pro-
vide improvements in clinical burden, patient experience and
healthcare costs. In Phase III trials, once-daily tiotropium (deliv-
ered via the Respimat® SoftMist™ inhaler) added on to at least
inhaled corticosteroids (ICS) improved lung function in patients
with symptomatic asthma. We investigated exacerbation risk in
each trial.
Methods Five Phase III, double-blind, placebo-controlled, paral-
lel-group trials in patients with symptomatic asthma. Patients
received tiotropium Respimat® 5 mg or placebo as add-on to at
least ICS maintenance therapy (Table). Pre-planned co-primary
or secondary end points were time to first severe exacerbation
and time to any asthma worsening.
Results Mean baseline% of predicted forced expiratory volume in
1 second, seven-question Asthma Control Questionnaire score and
ICS dose (mg) were: 56.0 ± 13.1, 2.6 ± 0.7, 1198 ± 539 (Primo-
TinA-asthma®); 75.1 ± 11.5, 2.2 ± 0.5, 660 ± 213 (MezzoTinA-
asthma®); 77.7 ± 11.9, 2.1 ± 0.4, 381 ± 78 (GraziaTinA-
asthma®). Tiotropium Respimat® 5 mg reduced severe asthma
exacerbation risk by at least 21% in all three severity cohorts
(Table) and asthma worsening risk versus placebo in all trials, with
a statistically significant reduction in the PrimoTinA-asthma® trial.
Conclusion Once-daily tiotropium Respimat® 5 mg add-on to at
least ICS maintenance therapy consistently reduced exacerba-
tions across asthma severities and so may be a beneficial add-on
option to reduce current and future exacerbation risk.
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Introduction The fixed-dose combination (FDC) of tiotropium
(T), a once-daily long-acting muscarinic antagonist, and oloda-
terol (O), a once-daily long-acting b2-agonist, is currently being
evaluated in chronic obstructive pulmonary disease (COPD).
Two 52-week, Phase III replicate pivotal studies were con-
ducted to assess the efficacy and safety of FDCs of T and O (T
+O) delivered via Respimat® Soft Mist™ inhaler in patients
(pts) with GOLD Stage 2–4 COPD. Pooled safety data from the
two studies are presented here.
Methods These were double-blind, randomised, parallel-group
studies with 5 arms: O 5 mg, T 2.5 mg, T 5 mg, T+O 2.5/5 mg,
T+O 5/5 mg. Key inclusion criteria were: age ≥40 years, diagno-
sis of COPD, smoking history >10 pack-years. Pts with a history
of asthma or significant disease other than COPD were
excluded. Adverse events (AEs) were reported throughout the
studies.
Results A total of 5162 pts were randomised and treated. In
general, AEs, serious AEs and fatal AEs were balanced across
treatment groups. In particular, frequencies of AEs in the cardiac
disorders System Organ Class (SOC) and respiratory disorders
SOC were similar.
Abstract P255 Table 1
Severe asthma exacerbations,
proportion of patients (%)
Trial
Background
medication
Tiotropium
Respimat® 5 mg Placebo
HRa
(95% CI) p value
PrimoTinA-
asthma®b
ICS + LABA
(>800 µg budesonide
or equivalent)
122/453
(26.9) 149/454 (32.8)
0.79
(0.62, 1.00) 0.034
MezzoTinA-
asthma®c
ICS (400–800 mg
budesonide or
equivalent)
31/513
(6.0)
43/518
(8.3)
0.72
(0.45, 1.14) 0.164
GraziaTinA-
asthma®d
ICS (200–400 mg
budesonide or
equivalent)
1/151
(0.7)
4/151
(2.6)
0.25
(0.03, 2.24) 0.216
aHazard ratio; time to first severe exacerbation (versus placebo, <1 favours tiotropium
Respimat®); bBaseline to Week 48; cBaseline to Week 24; dBaseline to time of last event
Abstract P256 Table 1
Pts with AE,%
O 5 mg
n = 1038
T 2.5 mg
n = 1032
T 5 mg
n = 1033
T+O
2.5/5 mg
n = 1030
T+O
5/5 mg
n = 1029
Total AEs 76.6 73.4 73.3 74.7 74.0
Serious AEs 17.4 15.1 16.7 16.3 16.4
Fatal AEs 1.3 1.2 1.6 1.4 1.7
Cardiac disorders* 5.7 5.8 5.3 5.8 4.5
Respiratory,
thoracic and
mediastinal disorders* 45.3 43.9 42.7 38.2 39.4
*MedDRA SOC
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